Dr. Rob Burgess shares how Sino Biological empowers global biomedical research through precision, quality, and ...
Scinai Immunotherapeutics Ltd. has acquired Recipharm Israel Ltd., operator of Recipharm’s manufacturing site in Yavne.
EpitogenX and Attomarker sign co-development agreement to advance precision immunology diagnostics in multiple diseases ...
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing ...
Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional ...
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) ...
ImmunityBio, Inc. , a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held ...
Continued expansion of LYTENAVA (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submit ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
The induction of respiratory mucosal immunity, characterized by secretory IgA (sIgA) and lung-resident memory T (TRM) cells, is essential for ...
Creative Diagnostics announces the release of a specialized portfolio of Antibiotic Residue Detection ELISA Kits. NEW ...
FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results